DDInter907 DDInter1676
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Iloperidone {u} (Compound) resembles {v} (Compound) Gefitinib
Iloperidone {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Iloperidone {u} (Compound) resembles {v} (Compound) Paliperidone
Iloperidone {u} (Compound) binds {v} (Gene) DRD1
Iloperidone {u} (Compound) upregulates {v} (Gene) PAK6
Iloperidone {u} (Compound) downregulates {v} (Gene) DKK3
Iloperidone {u} (Compound) causes {v} (Side Effect) Menstruation irregular
Iloperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clidinium
Iloperidone (Compound) resembles Gefitinib (Compound)
Iloperidone may lead to a major life threatening interaction when taken with Cisapride
Iloperidone (Compound) resembles Paliperidone (Compound)
Iloperidone (Compound) binds DRD1 (Gene)
Iloperidone (Compound) upregulates PAK6 (Gene)
Iloperidone (Compound) downregulates DKK3 (Gene)
Iloperidone (Compound) causes Menstruation irregular (Side Effect)
Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Clidinium